Phase 4 Pancreatitis Trial, Recruiting NCT07418593 Sponsor: Anna Evans Phillips Condition: Pancreatitis
Back to Pancreatitis

Phase 4 Pancreatitis Trial, Recruiting

NCT07418593
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have had recurring episodes of pancreatitis (at least 2 documented attacks in your lifetime, meeting certain medical criteria) OR you have been diagnosed with chronic pancreatitis of a specific severity level
  • A recent stool test (within the last 12 months) showed your pancreas is still producing a certain level of digestive enzymes (fecal elastase score of 50 or above)

Who may not be able to join:

  • You have a known allergy or intolerance to pancreatic enzyme replacement therapy or a related treatment used in this trial
  • You are currently taking medications that affect how your body absorbs fat, or supplements containing the specific fatty acids being studied in this trial (for example, orlistat, ursodeoxycholic acid, or Fatty-15 supplements)
  • You are currently taking a type of diabetes or weight management medication known as a GLP-1 receptor agonist (for example, medications like semaglutide or liraglutide)
  • Your recent stool test showed very low digestive enzyme levels, you have already been diagnosed with severe pancreatic insufficiency, or you are currently experiencing ongoing fatty/oily stools
  • You have been taking pancreatic enzyme replacement therapy for more than 5 days within the last 30 days
  • You have had a documented pancreatitis attack within the last 90 days
  • You have previously had surgery to remove part of your pancreas, or you have a condition that affects how your body absorbs nutrients
  • You are currently pregnant or breastfeeding
  • You have another serious medical condition that the lead doctor running the trial considers would make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Anna E Phillips, MD MS, University of Pittsburgh

Phone: 412-864-7096

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Anna Evans Phillips
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Primary Outcome (Aim 1); Primary Outcome (Aim 2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov